Search Results - "JUNICHI SHIMIZU"

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer by Yoshida, Tatsuya, Oya, Yuko, Tanaka, Kosuke, Shimizu, Junichi, Horio, Yoshitsugu, Kuroda, Hiroaki, Sakao, Yukinori, Hida, Toyoaki, Yatabe, Yasushi

“…Anaplastic lymphoma kinase (ALK) rearrangement-positive non-small-cell lung cancers can be effectively treated with an ALK tyrosine kinase inhibitor (TKI) such…”
Get full text

Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non‐small cell lung cancer by Kagawa, Yusuke, Furuta, Hiromi, Uemura, Takehiro, Watanabe, Naohiro, Shimizu, Junichi, Horio, Yoshitsugu, Kuroda, Hiroaki, Inaba, Yoshitaka, Kodaira, Takeshi, Masago, Katsuhiro, Fujita, Shiro, Niimi, Akio, Hida, Toyoaki

“…Immune checkpoint inhibitors (ICIs) have dramatically changed the strategy used to treat patients with non‐small‐cell lung cancer (NSCLC); however, the vast…”
Get full text

Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer by Oya, Yuko, Yoshida, Tatsuya, Kuroda, Hiroaki, Mikubo, Masashi, Kondo, Chiaki, Shimizu, Junichi, Horio, Yoshitsugu, Sakao, Yukinori, Hida, Toyoaki, Yatabe, Yasushi

“…Nivolumab offers a superior survival benefit over docetaxel in patients with advanced, previously treated non-small-cell lung cancer (NSCLC). An association…”
Get full text

Efficacy of chemotherapy plus immune checkpoint inhibitors in patients with non-small cell lung cancer who have rare oncogenic driver mutations: a retrospective analysis by Yamaguchi, Teppei, Shimizu, Junichi, Matsuzawa, Reiko, Watanabe, Naohiro, Horio, Yoshitsugu, Fujiwara, Yutaka

“…Targeted therapy is now the standard of care in driver-oncogene-positive non-small cell lung cancer (NSCLC). Its initial clinical effects are remarkable…”
Get full text

Multiplex gene‐panel testing for lung cancer patients by Yatabe, Yasushi, Sunami, Kuniko, Goto, Koichi, Nishio, Kazuto, Aragane, Naoko, Ikeda, Sadakatsu, Inoue, Akira, Kinoshita, Ichiro, Kimura, Hideharu, Sakamoto, Tomohiro, Satouchi, Miyako, Shimizu, Junichi, Tsuta, Koji, Toyooka, Shinichi, Nishino, Kazumi, Hatanaka, Yutaka, Matsumoto, Shingo, Mikubo, Masashi, Yokose, Tomoyuki, Dosaka‐Akita, Hirotoshi

“…The year 2019 was considered to be the first year of cancer genome medicine in Japan, with three gene‐panel tests using next‐generation sequencing (NGS)…”
Get full text

Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis by Yamaguchi, Teppei, Shimizu, Junichi, Hasegawa, Takaaki, Horio, Yoshitsugu, Inaba, Yoshitaka, Hanai, Nobuhiro, Muro, Kei, Hida, Toyoaki

“…Background Nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody, has shown survival benefit in clinical trials of various malignant tumors…”
Get full text

Impact of different bilateral knee extension strengths on lower extremity performance by Cho, Kilchoon, Suzuki, Makoto, Iso, Naoki, Okabe, Takuhiro, Goto, Hiroshi, Hirata, Keisuke, Shimizu, Junichi

“…Despite the impact of leg muscle strength on lower extremity motor performance-including walking and sit-to-stand transfer-it remains difficult to predict the…”
Get full text

Using machine learning to investigate the relationship between domains of functioning and functional mobility in older adults by Hirata, Keisuke, Suzuki, Makoto, Iso, Naoki, Okabe, Takuhiro, Goto, Hiroshi, Cho, Kilchoon, Shimizu, Junichi

“…Previous studies have shown that functional mobility, along with other physical functions, decreases with advanced age. However, it is still unclear which…”
Get full text

Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer by TATEMATSU, Akiko, SHIMIZU, Junichi, MURAKAMI, Yoshiko, HORIO, Yoshitsugu, NAKAMURA, Shigeo, HIDA, Toyoaki, MITSUDOMI, Tetsuya, YATABE, Yasushi

“…Purpose: The vast majority of epidermal growth factor receptor ( EGFR ) mutations occur in lung adenocarcinoma, and even rare cases of other subtypes with this…”
Get full text

The incidence of drug-induced interstitial lung disease caused by epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors in patients with non-small cell lung cancer in presence and absence of vascular endothelial growth factor inhibitors: a systematic review by Fujiwara, Yutaka, Shimomura, Kazuhiro, Yamaguchi, Teppei, Shimizu, Junichi, Watanabe, Naohiro, Matsuzawa, Reiko, Murotani, Kenta, Horio, Yoshitsugu

“…Interstitial lung disease (ILD) or pneumonitis caused by epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) or immune checkpoint…”
Get full text

EGFR Mutation Impact on Definitive Concurrent Chemoradiation Therapy for Inoperable Stage III Adenocarcinoma by Tanaka, Kosuke, Hida, Toyoaki, Oya, Yuko, Oguri, Tomoyo, Yoshida, Tatsuya, Shimizu, Junichi, Horio, Yoshitsugu, Hata, Akito, Kaji, Reiko, Fujita, Shiro, Sekido, Yoshitaka, Kodaira, Takeshi, Kokubo, Masaki, Katakami, Nobuyuki, Yatabe, Yasushi

“…Concurrent chemoradiation therapy (CRT) is the current standard of care for patients with locally advanced lung adenocarcinoma; however, little has been…”
Get more information

Drug-Induced Liver Injury in a Patient with Nonsmall Cell Lung Cancer after the Self-Administration of Fenbendazole Based on Social Media Information by Yamaguchi, Teppei, Shimizu, Junichi, Oya, Yuko, Horio, Yoshitsugu, Hida, Toyoaki

“…Fenbendazole is a benzimidazole anthelmintic agent, with a broad antiparasitic range in animals such as dogs and pigs. The agent is also reported to exert…”
Get full text

Sex Differences in Age-Related Physical Changes among Community-Dwelling Adults by Okabe, Takuhiro, Suzuki, Makoto, Goto, Hiroshi, Iso, Naoki, Cho, Kilchoon, Hirata, Keisuke, Shimizu, Junichi

“…The prevalence of physical functioning limitations is positively correlated with age in both men and women. However, whether the appearance of deterioration…”
Get full text

Biomarker testing for personalized, first-line therapy in advanced nonsquamous non-small cell lung cancer patients in the real world setting in Japan: a retrospective, multicenter, observational study (the BRAVE study) by Shimizu, Junichi, Masago, Katsuhiro, Saito, Haruhiro, Nishino, Kazumi, Kurata, Takayasu, Itoh, Yohji, Yoshimura, Yoko, Yabuki, Yutaka, Dosaka-Akita, Hirotoshi

“…Background: Molecular diagnostic testing is necessary to guide optimal first-line treatment. The number of patients who receive first-line treatment based on…”
Get full text

Pulmonary infections mimicking malignancy on bronchoscopy: A retrospective single‐center study in Japan by Itoh, Naoya, Shimizu, Junichi, Murakami, Hiromi, Hida, Toyoaki

“…Background Pulmonary infections can imitate pulmonary neoplasms. Pulmonary tuberculosis (TB) is a typical example of an infection that mimics cancer and…”
Get full text

Clinical Outcomes of Platinum-based Chemotherapy According to T790M Mutation Status in EGFR-Positive Non-Small Cell Lung Cancer Patients after Initial EGFR-TKI Failure by Yoshida, Tatsuya, Kuroda, Hiroaki, Oya, Yuko, Shimizu, Junichi, Horio, Yoshitsugu, Sakao, Yukinori, Hida, Toyoaki, Yatabe, Yasushi

“…Highlights • We evaluated the efficacy of platinum-based chemotherapy according to the EGFR T790M status. • We retrospectively reviewed 50 EGFR-positive NSCLC…”
Get full text

Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation by Oya, Yuko, Yoshida, Tatsuya, Kuroda, Hiroaki, Shimizu, Junichi, Horio, Yoshitsugu, Sakao, Yukinori, Inaba, Yoshitaka, Hida, Toyoaki, Yatabe, Yasushi

“…Progression patterns at the time of resistance to the initial epidermal growth factor receptor (EFGR)-tyrosine kinase inhibitors are clinically heterogeneous…”
Get full text

Propensity score–weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non–small cell lung cancer (WJOG10217L) by Kato, Ryoji, Hayashi, Hidetoshi, Chiba, Yasutaka, Miyawaki, Eriko, Shimizu, Junichi, Ozaki, Tomohiro, Fujimoto, Daichi, Toyozawa, Ryo, Nakamura, Atsushi, Kozuki, Toshiyuki, Tanaka, Kentaro, Teraoka, Shunsuke, Usui, Kazuhiro, Nishino, Kazumi, Hataji, Osamu, Ota, Keiichi, Ebi, Noriyuki, Saeki, Sho, Akazawa, Yuki, Okuno, Motoyasu, Yamamoto, Nobuyuki, Nakagawa, Kazuhiko

“…BackgroundStudies have suggested that chemotherapy after immune checkpoint inhibitors may confer an improved response for non–small cell lung cancer (NSCLC)…”
Get full text

Risk factors for pneumonitis in patients with non‐small cell lung cancer treated with immune checkpoint inhibitors plus chemotherapy: A retrospective analysis by Yamaguchi, Teppei, Shimizu, Junichi, Oya, Yuko, Watanabe, Naohiro, Hasegawa, Takaaki, Horio, Yoshitsugu, Inaba, Yoshitaka, Fujiwara, Yutaka

“…Background Immune checkpoint inhibitor (ICI) therapy plus chemotherapy has become a standard of care for patients with advanced non‐small cell lung cancer…”
Get full text

Salvage surgery for small cell lung cancer after chemoradiotherapy by Nakanishi, Keita, Mizuno, Tetsuya, Sakakura, Noriaki, Kuroda, Hiroaki, Shimizu, Junichi, Hida, Toyoaki, Yatabe, Yasushi, Sakao, Yukinori

“…There are few reports on the use of salvage surgery for small cell lung cancer (SCLC). Five patients who underwent resection of post-chemoradiotherapy residual…”
Get full text